Articles and Videos
Loading...
April 4, 2022
Forbes Health: What is CBN?
Forbes reporter Lauren Silva dives into the science behind rare cannabinoid, cannabinol, also known as CBN. The article features clinical and preclinical research conducted on...
March 28, 2022
Peer-reviewed journal article: “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”
INM-088 Study on the Use of CBN as a Potential Treatment for Glaucoma published in Peer-Reviewed Article InMed's research of INM-088, a cannabinol formulation...
March 9, 2022
Ophthalmology Times: Blog: Cannabinol, a rare cannabinoid, shows unique therapeutic potential in glaucoma
Excerpt from Ophthalmology Times blog. A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some...
February 22, 2022
Ophthalmology Advisor: Cannabinoids May Promote Neuroprotection, Normalize Intraocular Pressure
Excerpt from Ophthalmology Advisor. Using in vitro and in vivo models of glaucoma, cannabinoids (CBs) demonstrated neuroprotection, stopped changes in extracellular matrix (ECM), and normalized intraocular pressure (IOP) levels...
February 3, 2022
Cannabinoids See Explosive Growth Opportunity | The Dales Report
BayMedica's VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry. In...
Source:
The Dales Report
January 25, 2022
InMed at Edison Open House Global Healthcare Conference 2022
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped...